Rhinomed Limited announced that it has received purchase orders confirming a major distribution expansion of its Pronto Clear nasal decongestion technology within one of the largest and leading pharmacy and drugstore chains in the USA. This major US drugstore chain currently stocks the Mute and Pronto Sleep technologies in its Sleep categories and has now placed orders for Pronto Clear. The retailer has confirmed that from September Rhinomed's Pronto Clear product will be ranged on shelf in the Cough, Cold and Flu category in 6,336 of its stores across the US. This major expansion means that the target Rhinomed set itself in late 2019, when it stated that its growth aspirations were underpinned by growing its store count from 13,000 to 20,000 stores globally by the end of the 2020 calendar year, has been achieved six months ahead of schedule. Pronto Clear addresses unmet needs in the USD 34 billion ($49.3 billion) global market for nasal decongestion, cough, cold and allergy treatments. Pronto Clear is a unique vapour inhaler that gently opens the nose and delivers a blend of six pure essential oils traditionally known to help clear a stuffy nose naturally. In a user trial with 60 people1, 89% of people who had a blocked or stuffy nose found Pronto cleared their noses before they fell asleep. Pronto Clear (and Pronto Sleep) is registered with the US Food & Drug Administration (FDA) and Australia's Therapeutic Goods Administration (TGA) as a Class 1 medical device, and also has the CE Mark clearance for sale in the European Union (EU). Pronto Clear retails for USD 16.99 a pack.